Diagnostics firm QuidelOrtho has joined with the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunisation, for a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients.
Maternal red blood cell alloimmunisation is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy foetal and neonatal red blood cells, causing haemolytic disease of the foetus and newborn (HDFN), a temporary but life-threatening condition that requires timely, specialised treatment. Many families struggle to find clear, early and actionable information, creating gaps in care that disproportionately affect underserved populations. This collaboration aims to change that.
Rooted in a shared purpose, QuidelOrtho and Allo Hope will jointly develop resources that elevate patient voices, increase awareness among healthcare providers and help ensure women receive informed, equitable prenatal testing and care from the very beginning.
"At QuidelOrtho, our mission is to advance diagnostics for a healthier future for all," said Bryan Hanson, Executive Vice President, Global Portfolio Management and Marketing, QuidelOrtho. "Through this collaboration with the Allo Hope Foundation, we are activating that mission in a meaningful new way, helping ensure alloimmunised patients receive the early testing, accurate information and compassionate support they deserve. This is the perfect moment to highlight how diagnostics can directly improve maternal health outcomes, especially for those who have historically been underserved."
The collaboration also reinforces a commitment to patient-centred authenticity.
"At Allo Hope, our work begins and ends with the patient experience," said Bethany Weathersby, Founder and Executive Director, Allo Hope Foundation. "Families facing alloimmunisation often feel overwhelmed and isolated. By collaborating with QuidelOrtho, we're able to bring together clinical expertise, trusted diagnostics and lived experience to provide education that is both accurate and deeply human. We're excited to broaden awareness and reach more families earlier, with clarity, compassion, and the support needed, to make survival the standard for children with HDFN."
Beginning this summer, QuidelOrtho and the Allo Hope Foundation will release a series of co-produced educational materials designed for both laboratory technicians and families. These educational assets will be made available through both organisations' digital channels.